Taizhou Kaimi Biotech and Scenesafe have announced a collaborative effort to launch the Unow™ Drug Residue Test Device in Canada, providing a portable solution for identifying trace amounts of dangerous substances in various environments.
The innovative device enables rapid testing for hazardous drug residues, including opioids, fentanyl, and methamphetamine, with laboratory-grade precision. Its user-friendly design delivers results within minutes, addressing critical safety needs across multiple professional sectors.
Key target markets include law enforcement, healthcare facilities, trauma scene remediation teams, and property managers. The device allows for immediate on-site testing, helping professionals quickly assess potential drug contamination risks in residential, commercial, and public spaces.
By combining Kaimi Biotech's technological expertise with Scenesafe's understanding of Canadian safety protocols, the partnership aims to establish a new standard in drug residue detection and environmental safety.
The Unow™ device represents a significant advancement in portable diagnostics, offering professionals a reliable tool to verify and mitigate potential health and safety risks associated with drug contamination. Its introduction reflects a proactive approach to addressing public health challenges through innovative technological solutions.
The device will become available to Canadian clients in the second quarter of 2025, with pre-orders expected to open soon.
